Marine Drugs Acting as Autophagy Modulators

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 8186

Special Issue Editors


E-Mail Website
Guest Editor
Tumor and Breast Center ZeTuP St. Gallen, Rorschacherstr. 150, CH-9006 St. Gallen, Switzerland
Interests: medical oncology; drug resistance; marine anti-cancer compounds; drug development; tumor biology; proteomics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Co-Guest Editor
1. Laboratory of Experimental Oncology, Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald-Tumorzentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2. Martini-Klinik, Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
Interests: marine natural compounds; secondary metabolites; anticancer activity; mechanism of action; autophagy; drug combinational studies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Compared to terrestrial life forms, marine inhabitants are by far less well studied organisms. At the same time, due to the special and often extreme environmental conditions they live in (high pressure, lack of light, salinity, pH), they harbor a unique variety of chemical compounds, and there are probably still many more to be discovered. A good proportion of these compounds exhibit potent biological activity, targeting one or several specific biological processes.

Autophagy is one of these processes, which has only recently received more attention. This cellular process, which is implicated in many aspects of human physiology and disease, including cancer, neurodegenerative conditions (Parkinson's and Alzheimer's disease), cardiomyopathy, and others, is essential for the survival and death of mammalian cells. It is an exciting perspective to find and develop compounds that have the ability to control and manipulate this process.

This Special Issue “Marine Drugs acting as Autophagy Modulators” of Marine Drugs will cover the whole scope from agents with autophagy-modulating activity, both novel to previously characterized, including already clinically used marine-derived compounds known to have the ability to modulate autophagy both in vitro and in vivo. The issue will present work on compounds that are able to modulate all the different types of autophagy—i.e., macroautophagy, microautophagy, and chaperone-mediated autophagy—with cytotoxic, cytoprotective, pro-survival, or noncytotoxic biological activity.

Since autophagy is a relatively new and sometimes still controversial topic, results of similar experiments are often interpreted in different ways. Therefore, for interpretation of experimental data submitted to this Special Issue, the guest editors suggest using the recommendations published by Klionsky et al. in the “Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)” (Autophagy. 2016;12(1):1-222; PMID: 26799652) as well as by Yoshii and Mizushima “Monitoring and Measuring Autophagy” (Int J Mol Sci. 2017;18(9):1865; PMID: 28846632)

Dr. Friedemann Honecker
Dr. Sergey A. Dyshlovoy
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

3 pages, 342 KiB  
Editorial
Marine Drugs Acting as Autophagy Modulators
by Sergey A. Dyshlovoy and Friedemann Honecker
Mar. Drugs 2020, 18(1), 53; https://doi.org/10.3390/md18010053 - 14 Jan 2020
Cited by 3 | Viewed by 2753
Abstract
Autophagy (Ancient Greek αὐτόφαγος [autóphagos]—“self-devouring”) is defined as a regulated mechanism of the degradation of unnecessary or dysfunctional cellular components [...] Full article
(This article belongs to the Special Issue Marine Drugs Acting as Autophagy Modulators)

Review

Jump to: Editorial

31 pages, 2980 KiB  
Review
Blue-Print Autophagy in 2020: A Critical Review
by Sergey A. Dyshlovoy
Mar. Drugs 2020, 18(9), 482; https://doi.org/10.3390/md18090482 - 21 Sep 2020
Cited by 8 | Viewed by 4913
Abstract
Autophagy is an elegant and complex biological process that has recently attracted much attention from the scientific community. The compounds which are capable of control and modulation of this process have a promising potential as therapeutics for a number of pathological conditions, including [...] Read more.
Autophagy is an elegant and complex biological process that has recently attracted much attention from the scientific community. The compounds which are capable of control and modulation of this process have a promising potential as therapeutics for a number of pathological conditions, including cancer and neurodegenerative disorders. At the same time, due to the relatively young age of the field, there are still some pitfalls in the autophagy monitoring assays and interpretation of the experimental data. This critical review provides an overview of the marine natural compounds, which have been reported to affect autophagy. The time period from the beginning of 2016 to the middle of 2020 is covered. Additionally, the published data and conclusions based on the experimental results are re-analyzed with regard to the guidelines developed by Klionsky and colleagues (Autophagy. 2016; 12(1): 1–222), which are widely accepted by the autophagy research community. Remarkably and surprisingly, more than half of the compounds reported to be autophagy activators or inhibitors could not ultimately be assigned to either category. The experimental data reported for those substances could indicate both autophagy activation and inhibition, requiring further investigation. Thus, the reviewed molecules were divided into two groups: having validated and non-validated autophagy modulatory effects. This review gives an analysis of the recent updates in the field and raises an important problem of standardization in the experimental design and data interpretation. Full article
(This article belongs to the Special Issue Marine Drugs Acting as Autophagy Modulators)
Show Figures

Figure 1

Back to TopTop